Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion LUNG-3: Zongertinib in early-stage NSCLC with HER2 mutations
NCT07195695Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2026
- Primary completion
- Feb 2032
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Zongertinib treatment arm with Standard of Care (SoC) treatment arm (2 arms). Primary endpoint: Disease-Free Survival. Started Jan 2026; status: recruiting.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07195695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195695.